The Alzheimer’s Drug Discovery Foundation (ADDF) has invested $4.2M to accelerate the development of GliaPharm’s lead compound through investigational new drug (IND)-enabling studies to gain approval for clinical testing in Alzheimer’s disease.

阿尔茨海默病药物发现基金会（ADDF）投资420万美元，通过研究性新药（IND）加速格列法姆先导化合物的开发，使研究获得批准用于阿尔茨海默病的临床试验。

GliaPharm SA is an EPFL Spinoff specialising in the research and development of novel therapies to treat and prevent neurological diseases. Founded in 2017, GliaPharm has established a pipeline of compounds through its in-house proprietary drug discovery platform GliaX focused on glial cell function.

GliaPharm SA是EPFL的分支机构，专门研究和开发治疗和预防神经系统疾病的新型疗法。GliaPharm成立于2017年，通过其专注于神经胶质细胞功能的内部专有药物发现平台GliaX建立了一条化合物管道。

These compounds aim to promote brain energy metabolism by specifically targeting glial cells..

这些化合物旨在通过特异性靶向神经胶质细胞来促进大脑能量代谢。。

One of the hallmarks of neurodegenerative diseases, such as Alzheimer’s, is reduced glucose uptake in the brain, a condition known as hypometabolism. This metabolic decline occurs before symptoms arise and persists as the disease progresses. There are currently no specific treatments to address this problem in Alzheimer’s disease. .

神经退行性疾病（如阿尔茨海默氏病）的标志之一是大脑中葡萄糖摄取减少，这种情况被称为低代谢。这种代谢下降发生在症状出现之前，并随着疾病的进展而持续。目前还没有专门的治疗方法来解决阿尔茨海默病的这个问题。。

The company is currently developing its lead candidate GP-119 towards clinical testing through IND/CTA-enabling studies, which are mandatory to gain approval for clinical testing by the Food and Drug Administration (FDA) in the US, and the European Medicines Agency (EMA) in Europe.

该公司目前正在通过IND/CTA启用研究开发其主要候选药物GP-119，以进行临床测试，这些研究必须获得美国食品和药物管理局（FDA）和欧洲药品管理局（EMA）的临床测试批准。

The $4.2 million investment from the Alzheimer’s Drug Discovery Foundation (ADDF), a non-profit organisation dedicated to accelerating drug discovery and development in Alzheimer’s disease, will bring GliaPharm’s lead compound GP-119 to the clinical stage. GP-119 is a novel, orally active small molecule that acts on brain energy metabolism. .

阿尔茨海默病药物发现基金会（ADDF）是一家致力于加速阿尔茨海默病药物发现和开发的非营利性组织，该基金会投资420万美元，将使GliaPharm的先导化合物GP-119进入临床阶段。GP-119是一种新型的口服活性小分子，可作用于大脑能量代谢。。

“While the brain is only about two percent of the body’s weight, it consumes about a quarter of the body’s energy in glucose stores, which is why it’s believed that poor brain metabolism can lead to neurodegeneration,” says Dr Howard Fillit, Co-Founder and Chief Science Officer at the ADDF. “Developing new drugs that seek to regulate brain metabolism in the ageing body like GliaPharm’s GP-119 is a promising approach for treating Alzheimer’s and related dementias, as we hope to develop an arsenal of drugs that can stop the disease in its tracks through combination therapy and precision medicine.” .

ADDF联合创始人兼首席科学官霍华德·菲利特（HowardFillit）博士说：“虽然大脑仅占体重的2%，但它在葡萄糖储存中消耗了人体约四分之一的能量，这就是为什么人们认为大脑代谢不良会导致神经退行性变。”。“开发像GliaPharm的GP-119这样寻求调节衰老身体大脑代谢的新药是治疗阿尔茨海默病和相关痴呆症的一种有前途的方法，因为我们希望开发一系列药物，通过联合治疗和精准医学来阻止疾病的发展。”。

“This comes as a strong validation for GliaPharm’s Alzheimer’s program and a solid partner for future developments,” adds Ambroise Magistretti, GliaPharm’s co-CEO and co-founder. “The support from the ADDF will be key to advancing our lead program through preclinical regulatory studies, which will be followed by clinical trials.

“这是对GliaPharm阿尔茨海默氏病项目的有力验证，也是未来发展的坚实合作伙伴，”GliaPharm联合首席执行官兼联合创始人安布罗斯·马吉斯特蒂（AmbroiseMagistretti）补充道。“ADDF的支持将是通过临床前监管研究推进我们领先项目的关键，随后将进行临床试验。

We are enthusiastic about the ADDF’s strategy to support novel and potentially complementary therapeutic solutions for Alzheimer’s disease, including our own approach to tackle brain hypometabolism,” says Dr. Charles Finsterwald, GliaPharm’s CSO and co-founder.(Press release/RAN)Image from rawpixel on FreePik.

GliaPharm的CSO和联合创始人查尔斯·芬斯特瓦尔德（CharlesFinsterwald）博士表示：“我们对ADDF支持阿尔茨海默氏病新型且可能互补的治疗方案的策略充满热情，包括我们自己解决大脑代谢不足的方法。”。（新闻稿/RAN）来自FreePik上rawpixel的图像。

0Comments

0注意事项

Back to all news

返回所有新闻

Please login

请登录

or sign up

或注册

to comment.

发表评论。

Commenting guidelines

评论指南

Send

发送